{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:45:21Z","timestamp":1791323121516,"version":"4.3.1"},"reference-count":144,"publisher":"Impact Journals, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,2,9]]},"DOI":"10.18632\/oncotarget.6658","type":"journal-article","created":{"date-parts":[[2015,12,24]],"date-time":"2015-12-24T10:31:04Z","timestamp":1450953064000},"page":"6521-6537","source":"Crossref","is-referenced-by-count":74,"title":["Novel strategies to target the ubiquitin proteasome system in multiple myeloma"],"prefix":"10.18632","volume":"7","author":[{"given":"Susanne","family":"Lub","sequence":"first","affiliation":[{"name":"Laboratory of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Maes","sequence":"additional","affiliation":[{"name":"Laboratory of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Menu","sequence":"additional","affiliation":[{"name":"Laboratory of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"De Bruyne","sequence":"additional","affiliation":[{"name":"Laboratory of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Vanderkerken","sequence":"additional","affiliation":[{"name":"Laboratory of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Van Valckenborgh","sequence":"additional","affiliation":[{"name":"Laboratory of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,12,18]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nature07960","article-title":"Targeting the ubiquitin system in cancer therapy","volume":"458","author":"Dikic","year":"2009","journal-title":"Nature"},{"key":"2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.blre.2013.10.002","article-title":"Targeting the ubiquitin proteasome system in haematological malignancies","volume":"27","author":"Irvine","year":"2013","journal-title":"Blood Rev"},{"key":"3","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/sj.cdd.4401702","article-title":"The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle","volume":"12","author":"Hershko","year":"2005","journal-title":"Cell Death Differ"},{"key":"4","first-page":"46","article-title":"The ubiquitin-proteasomal system is critical for multiple myeloma : implications in drug discovery","volume":"1","author":"Mao","year":"2011","journal-title":"Am J Blood Res"},{"key":"5","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.tibs.2003.09.005","article-title":"Distinct monoubiquitin signals in receptor endocytosis","volume":"28","author":"Dikic","year":"2003","journal-title":"Trends Biochem Sci"},{"key":"6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(03)00081-1","article-title":"The proteasome: structure, function, and role in the cell","volume":"29","author":"Adams","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"7","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/80992","article-title":"A gated channel into the proteasome core particle","volume":"7","author":"Finley","year":"2000","journal-title":"Nat Struct Biol"},{"key":"8","doi-asserted-by":"crossref","unstructured":"A prize for protein degradation. Nat Cell Biol. 2004; 6:1011.","DOI":"10.1038\/ncb1104-1011"},{"key":"9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nature07958","article-title":"Origin and Function of Ubiquitin-like Protein Conjugation","volume":"458","author":"Hochstrasser","year":"2009","journal-title":"Nature"},{"key":"10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1146\/annurev.cellbio.22.010605.093503","article-title":"Modification of proteins by ubiquitin and ubiquitin-like proteins","volume":"22","author":"Hochstrasser","year":"2006","journal-title":"Annu Rev Cell Dev Biol"},{"key":"11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd3321","article-title":"Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets","volume":"10","author":"Brownell","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1177\/1947601910382898","article-title":"The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy","volume":"1","author":"Brownell","year":"2010","journal-title":"Genes Cancer"},{"key":"13","first-page":"2197","article-title":"Multiple myeloma","volume":"385","author":"Bornh\u00e4user","year":"2014","journal-title":"Lancet"},{"key":"14","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/cancers5020430","article-title":"Epigenetic modulating agents as a new therapeutic approach in multiple myeloma","volume":"5","author":"De Bruyne","year":"2013","journal-title":"Cancers (Basel)"},{"key":"15","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","article-title":"Frontline therapy of multiple myeloma","volume":"125","author":"Facon","year":"2015","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012","volume":"49","author":"Bray","year":"2013","journal-title":"Eur J Cancer"},{"key":"17","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ajh.23810","article-title":"Multiple Myeloma : 2014 update on diagnosis, risk-stratification and management","volume":"89","author":"Rajkumar","year":"2014","journal-title":"Am J Hematol"},{"key":"18","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma : a population-based study","volume":"116","author":"Landgren","year":"2010","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma : a prospective study","volume":"113","author":"Rajkumar","year":"2009","journal-title":"Blood"},{"key":"20","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Hajek","year":"2010","journal-title":"Leukemia"},{"key":"21","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Kuehl","year":"2009","journal-title":"Blood"},{"key":"22","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma","volume":"356","author":"Rajkumar","year":"2007","journal-title":"N Engl J Med"},{"key":"23","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Dispenzieri","year":"2014","journal-title":"Lancet Oncol"},{"key":"24","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma","volume":"369","author":"L\u00f3pez","year":"2013","journal-title":"N Engl J Med"},{"key":"25","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10147-015-0837-0","article-title":"Molecular pathogenesis of multiple myeloma","volume":"20","author":"Kikuchi","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/B978-0-12-386469-7.00002-5","article-title":"The microenvironment and molecular biology of the multiple myeloma tumor","volume":"110","author":"Vanderkerken","year":"2011","journal-title":"Adv Cancer Res"},{"key":"27","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.beha.2007.08.004","article-title":"Genetic events in the pathogenesis of multiple myeloma","volume":"20","author":"Kuehl","year":"2007","journal-title":"Best Pr Res Clin Haematol"},{"key":"28","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-10-1843","article-title":"Genomics in Multiple Myeloma","volume":"17","author":"Avet-Loiseau","year":"2011","journal-title":"Clin Cancer Res"},{"key":"29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1586\/era.13.9","article-title":"Proteasome inhibitors in the treatment of multiple myeloma","volume":"13","author":"Ryan","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"key":"30","first-page":"3071","article-title":"The Proteasome Inhibitor PS-341 Inhibits Growth, Induces Apoptosis, and Overcomes Drug Resistance in Human Multiple Myeloma Cells","volume":"61","author":"Anderson","year":"2001","journal-title":"Cancer Res"},{"key":"31","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells","volume":"114","author":"Anderson","year":"2009","journal-title":"Blood"},{"key":"32","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","article-title":"Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341","volume":"101","author":"Anderson","year":"2003","journal-title":"Blood"},{"key":"33","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1158\/0008-5472.CAN-06-4322","article-title":"Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma","volume":"67","author":"Amiot","year":"2007","journal-title":"Cancer Res"},{"key":"34","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Boise","year":"2006","journal-title":"Blood"},{"key":"35","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents : therapeutic applications","volume":"101","author":"Munshi","year":"2003","journal-title":"Blood"},{"key":"36","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/0008-5472.CAN-05-1195","article-title":"Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells","volume":"66","author":"Anderson","year":"2006","journal-title":"Cancer Res"},{"key":"37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-0609.2006.00692.x","article-title":"Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment","volume":"77","author":"Sezer","year":"2006","journal-title":"Eur J Haematol"},{"key":"38","first-page":"2487","article-title":"Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma","volume":"24","author":"Blad\u00e9","year":"2005","journal-title":"N Engl J Med"},{"key":"39","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma","volume":"348","author":"Kuter","year":"2003","journal-title":"N Engl J Med"},{"key":"40","first-page":"420","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Depcik-Smith","year":"2002","journal-title":"J Clin Oncol"},{"key":"41","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma","volume":"359","author":"Cakana","year":"2008","journal-title":"N Engl J Med"},{"key":"42","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","article-title":"U.S. FDA approval for the treatment of Multiple Myeloma Progressing on Prior Therapy","volume":"8","author":"Pazdur","year":"2003","journal-title":"Oncologist"},{"key":"43","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","article-title":"United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy","volume":"12","author":"Pazdur","year":"2006","journal-title":"Clin cancer Res"},{"key":"44","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3109\/10428194.2010.483303","article-title":"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies","volume":"51","author":"Jakubowiak","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"45","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Cavet","year":"2011","journal-title":"Lancet Oncol"},{"key":"46","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1042\/BST20140126","article-title":"Overcoming bortezomib resistance in multiple myeloma","volume":"42","author":"Bowles","year":"2014","journal-title":"Biochem Soc Trans"},{"key":"47","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/j.seminhematol.2012.04.010","article-title":"Bortezomib Combination Therapy in Multiple Myeloma","volume":"49","author":"Rajkumar","year":"2012","journal-title":"Semin Hematol"},{"key":"48","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Garcia","year":"2010","journal-title":"Cancer Res"},{"key":"49","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1158\/1078-0432.CCR-11-0476","article-title":"andselective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells","volume":"17","author":"Anderson","year":"2011","journal-title":"Clin cancer Res"},{"key":"50","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-01-548826","article-title":"Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients","volume":"124","author":"Hui","year":"2014","journal-title":"Blood"},{"key":"51","doi-asserted-by":"crossref","first-page":"7313","DOI":"10.1158\/1078-0432.CCR-11-0636","article-title":"Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies","volume":"17","author":"Tayber","year":"2011","journal-title":"Clin cancer Res"},{"key":"52","first-page":"e338","article-title":"Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib","volume":"4","author":"Bergsagel","year":"2015","journal-title":"Blood Cancer J"},{"key":"53","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2141.2009.08008.x","article-title":"The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan","volume":"148","author":"Berenson","year":"2010","journal-title":"Br J Haematol"},{"key":"54","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2007-07-100651","article-title":"CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib","volume":"111","author":"Pescalli","year":"2008","journal-title":"Blood"},{"key":"55","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.leukres.2012.07.018","article-title":"CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma","volume":"36","author":"Berenson","year":"2012","journal-title":"Leuk Res"},{"key":"56","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejca.2012.09.009","article-title":"A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma","volume":"49","author":"Cereda","year":"2013","journal-title":"Eur J Cancer"},{"key":"57","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/jcmm.12279","article-title":"Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma","volume":"18","author":"Sevcikova","year":"2014","journal-title":"J Cell Mol Med"},{"key":"58","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Sun","year":"2007","journal-title":"Cancer Res"},{"key":"59","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Orlowski","year":"2007","journal-title":"Blood"},{"key":"60","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma","volume":"19","author":"Adams","year":"2013","journal-title":"Clin cancer Res"},{"key":"61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2013.10.018","article-title":"New orally active proteasome inhibitors in multiple myeloma","volume":"38","author":"Musolino","year":"2014","journal-title":"Leuk Res"},{"key":"62","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/jm801329v","article-title":"Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)","volume":"52","author":"Muchamuel","year":"2009","journal-title":"J Med Chem"},{"key":"63","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/leu.2012.183","article-title":"The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects","volume":"27","author":"San Miguel","year":"2013","journal-title":"Leukemia"},{"key":"64","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/anie.200390115","article-title":"Salinosporamide A: A Highly Cytotoxic Proteasome Inhibitor from a Novel Microbial Source, a Marine Bacterium of the New Genus Salinospora","volume":"42","author":"John","year":"2003","journal-title":"Angew Chemie Int Ed"},{"key":"65","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib","volume":"8","author":"Nicholson","year":"2005","journal-title":"Cancer Cell"},{"key":"66","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood-2009-03-213009","article-title":"Combination of novel proteasome inhibitor NPI-0052 and lenalidomide triggerandsynergistic cytotoxicity in multiple myeloma","volume":"115","author":"Anderson","year":"2010","journal-title":"Blood"},{"key":"67","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2007-08-105601","article-title":"Combination of proteasome inhibitors bortezomib and NPI-0052 triggersynergistic cytotoxicity in multiple myeloma","volume":"111","author":"Anderson","year":"2008","journal-title":"Blood"},{"key":"68","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.febslet.2013.11.003","article-title":"Development of inhibitors in the ubiquitination cascade","volume":"588","author":"Sidhu","year":"2014","journal-title":"FEBS Lett"},{"key":"69","doi-asserted-by":"crossref","first-page":"23010","DOI":"10.1074\/jbc.C700111200","article-title":"UBE1L2, a novel E1 enzyme specific for ubiquitin","volume":"282","author":"Groettrup","year":"2007","journal-title":"J Biol Chem"},{"key":"70","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2009-07-231191","article-title":"The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma","volume":"115","author":"Zavareh","year":"2010","journal-title":"Blood"},{"key":"71","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrd2056","article-title":"Drug discovery in the ubiquitin-proteasome system","volume":"5","author":"Harper","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"72","first-page":"619","article-title":"Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53","volume":"28","author":"Perantoni","year":"2010","journal-title":"Oncogene"},{"key":"73","doi-asserted-by":"crossref","first-page":"9472","DOI":"10.1158\/0008-5472.CAN-07-0568","article-title":"Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics","volume":"67","author":"Beutler","year":"2007","journal-title":"Cancer Res"},{"key":"74","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/1087057111433843","article-title":"Identification and mechanistic studies of a novel ubiquitin E1 inhibitor","volume":"17","author":"Liu","year":"2012","journal-title":"J Biomol Screen"},{"key":"75","first-page":"12","article-title":"JS-K, a glutathione\/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells","author":"Cronauer","year":"2012","journal-title":"BMC Cancer"},{"key":"76","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.bcp.2010.08.011","article-title":"JS-K; a nitric oxide-releasing prodrug, modulates ??-catenin\/TCF signaling in leukemic Jurkat cells: Evidence of an S-nitrosylated mechanism","volume":"80","author":"Kashfi","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"77","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/jcp.10380","article-title":"JS-K, a Novel Non-Ionic Diazeniumdiolate Derivative, Inhibits Hep 3B Hepatoma Cell Growth and Induces c-Jun Phosphorylation via Multiple MAP Kinase Pathways","volume":"197","author":"Carr","year":"2003","journal-title":"J Cell Physiol"},{"key":"78","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2006-10-052845","article-title":"JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosisandin human multiple myeloma cells","volume":"110","author":"Mitsiades","year":"2007","journal-title":"Blood"},{"key":"79","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1211\/jpp.62.01.0017","article-title":"JS-K has potent anti-angiogenic activityand inhibits tumour angiogenesis in a multiple myeloma model","volume":"62","author":"Jia","year":"2010","journal-title":"J Pharm Pharmacol"},{"key":"80","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.2174\/13816128113199990300","article-title":"Cullin-RING Ligases as attractive anti-cancer targets","volume":"19","author":"Sun","year":"2013","journal-title":"Curr Pharm Des"},{"key":"81","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1182\/blood-2013-08-521914","article-title":"MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells","volume":"123","author":"Lonial","year":"2014","journal-title":"Blood"},{"key":"82","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.molcel.2009.12.024","article-title":"Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ","volume":"37","author":"Lingaraj","year":"2010","journal-title":"Mol Cell"},{"key":"83","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1158\/1535-7163.MCT-11-0563","article-title":"Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma","volume":"11","author":"Mitsiades","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"84","article-title":"NEDD8 inhibition overcomes CKS1B induced drug resistance by upregulation of p21 in multiple myeloma","author":"Zhan","year":"2015","journal-title":"Clin Cancer Res"},{"key":"85","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1096\/fj.09-136259","article-title":"The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins","volume":"24","author":"Timmers","year":"2010","journal-title":"FASEB J"},{"key":"86","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1038\/sj.onc.1207458","article-title":"Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib\/Proteasome inhibitor PS-341","volume":"23","author":"Anderson","year":"2004","journal-title":"Oncogene"},{"key":"87","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.cell.2011.05.039","article-title":"An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme","volume":"145","author":"Wasney","year":"2011","journal-title":"Cell"},{"key":"88","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1593\/neo.06376","article-title":"E3 ubiquitin ligases as cancer targets and biomarkers","volume":"8","author":"Sun","year":"2006","journal-title":"Neoplasia"},{"key":"89","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nsmb.2780","article-title":"New insights into ubiquitin E3 ligase mechanism","volume":"21","author":"Wolberger","year":"2014","journal-title":"Nat Struct Mol Biol"},{"key":"90","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0006-291X(03)00245-6","article-title":"U-box proteins as a new family of ubiquitin ligases","volume":"302","author":"Nakayama","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"91","article-title":"p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma","volume":"2014","author":"Chng","year":"2014","journal-title":"Biomed Res Int"},{"key":"92","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1182\/blood.V90.5.1982","article-title":"MDM2 Protein Overexpression Promotes Proliferation and Survival of Multiple Myeloma Cells","volume":"90","author":"Anderson","year":"1997","journal-title":"Blood"},{"key":"93","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2","volume":"303","author":"Liu","year":"2004","journal-title":"Science"},{"key":"94","first-page":"2539","article-title":"p53 and RAS gene mutations in multiple myeloma","volume":"7","author":"Heillet","year":"1992","journal-title":"Oncogene"},{"key":"95","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V92.3.802","article-title":"Presence of a p53 Gene Deletion in Patients With Multiple Myeloma Predicts for Short Survival After Conventional-Dose Chemotherapy","volume":"92","author":"Heinz","year":"1998","journal-title":"Blood"},{"key":"96","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2004-04-1363","article-title":"p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation","volume":"105","author":"Stewart","year":"2005","journal-title":"Blood"},{"key":"97","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1182\/blood-2005-04-1489","article-title":"Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma","volume":"106","author":"Bargou","year":"2005","journal-title":"Blood"},{"key":"98","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4161\/cbt.10.6.12535","article-title":"Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma","volume":"10","author":"Chang","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"99","doi-asserted-by":"crossref","first-page":"936","DOI":"10.4161\/cbt.9.11.11882","article-title":"MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity","volume":"9","author":"Chang","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"100","doi-asserted-by":"crossref","first-page":"7153","DOI":"10.1158\/1078-0432.CCR-09-1071","article-title":"Interactions of the Hdm2\/p53 and Proteasome Pathways May Enhance the Antitumor Activity of Bortezomib","volume":"15","author":"Paul","year":"2009","journal-title":"Clin Cancer Res"},{"key":"101","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1038\/onc.2011.185","article-title":"Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3","volume":"30","author":"Maki","year":"2011","journal-title":"Oncogene"},{"key":"102","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm1146","article-title":"Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors","volume":"10","author":"Selivanova","year":"2004","journal-title":"Nat Med"},{"key":"103","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1158\/1535-7163.MCT-10-0471","article-title":"RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic Responses","volume":"9","author":"Chang","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"104","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1158\/1535-7163.MCT-12-0135","article-title":"Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA","volume":"11","author":"Orlowski","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"105","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/1471-2407-14-437","article-title":"RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway","volume":"14","author":"Pellat-Deceunynck","year":"2014","journal-title":"BMC Cancer"},{"key":"106","doi-asserted-by":"crossref","first-page":"e30215","DOI":"10.1371\/journal.pone.0030215","article-title":"Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma","volume":"7","author":"Chang","year":"2012","journal-title":"PLoS One"},{"key":"107","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1021\/jm051122a","article-title":"Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2 - p53 Interaction","volume":"49","author":"Krajewski","year":"2006","journal-title":"J Med Chem"},{"key":"108","doi-asserted-by":"crossref","first-page":"e103015","DOI":"10.1371\/journal.pone.0103015","article-title":"Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737","volume":"9","author":"Orlowski","year":"2014","journal-title":"PLoS One"},{"key":"109","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.canlet.2011.08.011","article-title":"Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activityand in tumor xenografts","volume":"312","author":"Deutsch","year":"2011","journal-title":"Cancer Lett"},{"key":"110","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.113.204958","article-title":"The Novel Anticancer Agent JNJ-26854165 Induces Cell Death through Inhibition of Cholesterol Transport and Degradation of ABCA1","volume":"346","author":"Orlowski","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"111","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.molcel.2008.03.008","article-title":"IAPs : What \u2019 s in a name ?","volume":"30","author":"Ashwell","year":"2008","journal-title":"Mol Cell"},{"key":"112","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrd3627","article-title":"Targeting IAP proteins for therapeutic intervention in cancer","volume":"11","author":"Vucic","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"113","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrm1621","article-title":"IAPs, RINGs and ubiquitylation","volume":"6","author":"Silke","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"key":"114","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/35022514","article-title":"Structural and biochemical basis of apoptotic activation by Smac\/DIABLO","volume":"406","author":"Shi","year":"2000","journal-title":"Nature"},{"key":"115","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/35050006","article-title":"Structural basis for binding of Smac\/DIABLO to the XIAP BIR3 domain","volume":"408","author":"Park","year":"2000","journal-title":"Nature"},{"key":"116","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/35050012","article-title":"Structural basis of IAP recognition by Smac\/DIABLO","volume":"408","author":"Du","year":"2000","journal-title":"Nature"},{"key":"117","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/leu.2014.56","article-title":"Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities","volume":"28","author":"Fulda","year":"2014","journal-title":"Leukemia"},{"key":"118","first-page":"a008730","article-title":"Inhibitor of Apoptosis (IAP) Proteins - Modulators of Cell Death and Inflammation","volume":"5","author":"Meier","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"119","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.20656","article-title":"IAP Family Protein Expression Correlates With Poor Outcome of Multiple Myeloma Patients in Association With Chemotherapy-induced Overexpression of Multidrug Resistance Genes","volume":"81","author":"Kitagawa","year":"2006","journal-title":"Am J Hematol"},{"key":"120","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1182\/blood-2006-04-015149","article-title":"Targeting mitochondrial factor Smac\/DIABLO as therapy for multiple myeloma (MM)","volume":"109","author":"Tran","year":"2007","journal-title":"Blood"},{"key":"121","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/leu.2014.2","article-title":"Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"122","doi-asserted-by":"publisher","first-page":"20621","DOI":"10.18632\/oncotarget.4139","article-title":"Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 - implications for a combinatorial treatment","volume":"6","author":"Vanderkerken","year":"2015","journal-title":"Oncotarget"},{"key":"123","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrc3700","article-title":"Roles of F-box proteins in cancer","volume":"14","author":"Wei","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"124","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nrm1471","article-title":"The SCF ubiquitin ligase: insights into a molecular machine","volume":"5","author":"Pagano","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"125","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0960-9822(99)80290-5","article-title":"p27 Kip1 ubiquitination and degradation is regulated by the SCF Skp2 complex through phosphorylated Thr187 in p27","volume":"9","author":"Zhang","year":"1999","journal-title":"Cur Biol"},{"key":"126","doi-asserted-by":"crossref","first-page":"25752","DOI":"10.1074\/jbc.M301774200","article-title":"Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase","volume":"278","author":"Hershko","year":"2003","journal-title":"J Biol Chem"},{"key":"127","doi-asserted-by":"crossref","first-page":"10231","DOI":"10.1073\/pnas.1831009100","article-title":"Degradation of p57 Kip2 mediated by SCF Skp2 - dependent ubiquitylation","volume":"100","author":"Imaki","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"128","first-page":"820","article-title":"Low p27 Kip1 Expression Is an Independent Adverse Prognostic Factor in Patients with Multiple Myeloma","volume":"9","author":"Drach","year":"2003","journal-title":"Clin Cancer Res"},{"key":"129","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10245330512331390140","article-title":"Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma","volume":"10","author":"Shaughnessy","year":"2005","journal-title":"Hematology"},{"key":"130","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1182\/blood-2007-09-112904","article-title":"Targeting the p27 E3 ligase SCF Skp2 results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy","volume":"111","author":"Nakayama","year":"2008","journal-title":"Blood"},{"key":"131","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/ncb2651","article-title":"SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2\/Tti1 degradation and promote survival in multiple myeloma","volume":"15","author":"Pagano","year":"2013","journal-title":"Nat Cell Biol"},{"key":"132","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Dalgleish","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"133","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a Primary Target of thalidomide teratogenicity","volume":"327","author":"Handa","year":"2010","journal-title":"Science"},{"key":"134","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Rychak","year":"2012","journal-title":"Leukemia"},{"key":"135","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Stewart","year":"2011","journal-title":"Blood"},{"key":"136","first-page":"1","article-title":"The APC\/C Ubiquitin Ligase: From Cell Biology to Tumorigenesis","author":"Ayad","year":"2011","journal-title":"Front Oncol"},{"key":"137","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrm1988","article-title":"The anaphase promoting complex\/cyclosome: a machine designed to destroy","volume":"7","author":"Peters","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"138","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1042\/BST0380137","article-title":"The therapeutic potential of deubiquitinating enzyme inhibitors","volume":"38","author":"Colland","year":"2010","journal-title":"Biochem Soc Trans"},{"key":"139","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.cell.2005.11.007","article-title":"A genomic and functional inventory of deubiquitinating enzymes","volume":"123","author":"Bernards","year":"2005","journal-title":"Cell"},{"key":"140","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.bbamcr.2004.10.003","article-title":"Mechanism and function of deubiquitinating enzymes","volume":"1695","author":"Hochstrasser","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"141","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2217\/14796694.3.2.191","article-title":"Deubiquitinating enzymes as novel anticancer targets","volume":"3","author":"Mattern","year":"2007","journal-title":"Futur Oncol"},{"key":"142","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature08646","article-title":"Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival","volume":"463","author":"Huang","year":"2010","journal-title":"Nature"},{"key":"143","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1182\/blood-2014-10-605584","article-title":"Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies","volume":"125","author":"Talpaz","year":"2015","journal-title":"Blood"},{"key":"144","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","article-title":"A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"22","author":"Hideshima","year":"2012","journal-title":"Cancer Cell"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T13:20:51Z","timestamp":1589203251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,18]]},"references-count":144,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,2,9]]}},"alternative-id":["6658","26695547"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.6658","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,18]]}}}